ClinicalTrials.gg
RecruitingNCT04019548SwallPEGUpdated May 10, 2023

Assessment of Swallowing Function and Quality of Life in Oropharyngeal Cancer Patients Treated by Chemo-radiotherapy

A Phase 3 interventional study of Percutaneous Endoscopic Gastrotomy tube placement and Cisplatin injection in Oropharyngeal Cancer, sponsored by Jules Bordet Institute. Recruiting at 2 sites in Belgium. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-05-10.

Sponsored by Jules Bordet Institute · Phase 3, Interventional, and Other

How we know

From the registry’s dates

  • Started Dec 2019; still recruiting 6 years 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 26 studies testing cisplatin in Oropharyngeal Neoplasms — 9 open to participants now, 18 under way, 5 of them phase 3. Cisplatin · Oropharyngeal Neoplasms.

Planned enrollment
13th of 26
110 · median 107
Started
2019
with 3 others
Phase 3
2 of 26
1 open now
Primary completion
2027-11
later than 10 of 17 live
Registered
12th of 26
by date

Among the 26 studies testing cisplatin in Oropharyngeal Neoplasms, this one is the 13th largest by planned enrollment, is one of 4 that started in 2019, is one of 2 in phase 3, reaches primary completion later than 10 of the 17 other live ones, and was the 12th registered.

Oropharyngeal Neoplasms

370 studies on the registry are indexed under Oropharyngeal Neoplasms; 104 are open to participants now.

Browse Oropharyngeal Neoplasms studies →

Open to participants now

9 of the 26 studies testing cisplatin in Oropharyngeal Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About cisplatin

Cisplatin: first FDA approval 1978 (PLATINOL-AQ). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 89 Oropharyngeal Neoplasms studies recruiting now, 76 (85%) set no upper age limit and 5 (6%) stop at 75 or younger; none take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 26 studies testing cisplatin in Oropharyngeal Neoplasms, or all of them as a file.
02

Study summary

Open-label, interventional, multicentric, randomized, phase III study. Cancer studied is the oropharyngeal cancer.

Study is composed by 2 arms of subjects: prophylactic or reactive percutaneous endoscopic gastrostomy tube placement.

All subjects will be treated with a cisplatin standard chemotherapy regimen and by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT).

Read the detailed description

Open-label, interventional, multicentric, randomized, phase III study. Cancer studied is the oropharyngeal cancer.

Study is composed by 2 arms of subjects (male or female): prophylactic or reactive percutaneous endoscopic gastrostomy tube placement.

The arm will be allocated by randomisation (1:1).

  • Prophylactic PEG (pPEG): Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.
  • Reactive PEG (rPEG): Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).

All subjects will be treated with a cisplatin standard chemotherapy regimen and by simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT).

Cisplatin: Two therapeutic regimens are allowed:

  • Days 1 and 22: cisplatin 100mg/m2 IV
  • Days 1,8,15,22,29 and 39: weekly cisplatin 40mg/m2 IV

Radiotherapy: The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.

Medical device: The medical device used in this trial is a percutaneous endoscopic gastrostomy tube with the CE label: CE0120. The medical device is used in the indication of the notice.

The estimated number of subjects to screen is 121 patients for an estimated number of 110 patients randomised for 100 evaluable patients.

The end of study will be declared when all the following criteria will have been met:

  • The study ends after last visit of the last patient remaining in the study.
  • The trial is mature for the analysis of the endpoints as defined in the protocol, if the trial reaches its endpoints.
  • The database has been fully cleaned and frozen for all analyses.
03

Conditions studied

  • Oropharyngeal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years old
  2. performance status ≤ 2
  3. Female and Male
  4. Newly diagnosed, confirmed primary squamous cell carcinoma of the oropharynx
  5. Candidate for curative intent radiotherapy and systemic treatment
  6. No prior or current anticancer treatment for the HNSCC (e.g. chemotherapy, surgery)
  7. Diagnosis results
  8. HPV/p 16 testing results
  9. Serum test (for subjects of ) negative within 7 days prior to the 1st CRT administration.
  10. Women of childbearing potential must agree to use of one highly effective method of prior study entry, during the course of the study and at least 6 months after the last administration of cisplatin.
  11. Men with childbearing potential partner must agree to use condom during the course of this study and for at least 6 months after the last administration of the cisplatin.
  12. Adequate bone marrow function as defined below:

    • (ANC) ≥1500/µL or 1.5x109/L
    • ≥ 9 g/dL
    • ≥100000/µL or 100x109/L
  13. Adequate liver function as defined below:

    • Serum total ≤ 1.5 x . In case of known Gilbert's syndrome \< 3 x UNL is allowed
    • (SGOT)/ALT (SGPT) ≤ 2.5 x ULN
    • Alkaline phosphatase ≤ 2.5 x ULN
  14. Adequate renal function as defined below:

    • Creatinine ≤ 1.5 x UNL and > 60 mL/min
  15. Peripheral neuropathy ≤ grade 1
  16. Hear impaired ≤ grade 1
  17. Completion of all necessary screening procedures within 15 days prior to randomisation.
  18. Signed form (ICF) obtained prior to any study related procedure.
  19. Ability to understand and complete the questionnaires (language proficiency, cognitive functioning) as judged by principal investigator upon screening

Exclusion criteria

Exclusion Criteria:

  1. Severe malnutrition
  2. Dysphagia requiring a liquid or puree texture modified diet (grade ≥ 2 (CTCAE_v.5)
  3. Distant
  4. Serious coagulation disorders (>1.5, PTT>50s, \<50000/mm3)
  5. Subject with a significant medical, neuro-psychiatric, or surgical condition, currently uncontrolled by treatment, which, in the principal investigator's opinion, may interfere with completion of the study.
  6. Other in the 3 years prior to study entry except of surgically cured carcinoma in situ of the cervix, in situ breast cancer, incidental finding of stage T1a or T1b prostate cancer, and basal/squamous cell carcinoma of the skin;
  7. Pregnant and/or lactating women.
  8. Known to the study drug (cisplatin) or .
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Prophylactic PEG

    Prophylactic PEG tube will be placed before the start of the study treatment (CRT). The enteral nutrition will start following the assessment by the clinical dietitian in order to complete the current oral consumption according to the estimated energy needs (on the basis of 30 to 35 kcal / kg adapted and 1.2 to 1.5 g / prot./ kg.BW) with an increase as needed during the treatment.

    Device: Percutaneous Endoscopic Gastrotomy tube placement · Drug: Cisplatin injection · Radiation: Radiotherapy

  • Experimental
    Reactive PEG

    Reactive PEG tube will be placed and enteral nutrition initiated, during the study treatment period in case of decrease of oral intake less than 2/3 of estimated energy requirements (based on 30-35 kcal / adapted kg .BW and 1.2 - 1.5 g/prot./adapted kg. BW) for a period of or anticipated to be, greater than 7 days or weight loss ≥ 5% from pre-treatment baseline).

    Device: Percutaneous Endoscopic Gastrotomy tube placement · Drug: Cisplatin injection · Radiation: Radiotherapy

Interventions

  • DevicePercutaneous Endoscopic Gastrotomy tube placement

    placement of the PEG tube depends on arm

  • DrugCisplatinStudies of CisplatinCisplatin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Two therapeutic regimen allowed: * Days 1 and 22 : cisplatin 100mg/m2 IV * Days 1,8,15,22,29,36: weekly cisplatin 40 mg/m2 IV

  • RadiationRadiotherapy

    Simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT). The median dose prescription will be 32 x 2.16 Gy to the high risk PTV and 32 x 1.75 Gy to the elective PTV.

06

What researchers measure

Primary outcomes

  1. global M.D. Anderson Dysphagia Inventory score at 6 months after end of treatment.

    The M.D.Anderson Dysphagia inventory is a dysphagia-specific quality-of-life questionnaire for patients with H\&N cancer including 20 items divided into 4 subscales emotional (6 questions), functional (5 questions), physical (8 questions) and one global question. Each subscale has a score ranging from 1 to 5 (higher scores represent a better outcome). The mean score of the 20 items will be multiplied by a factor of 20 to obtain a MDADI total score which ranges from 20 (extremely low functioning) to 100 (high functioning). A difference of 8 points in MDADI score is considered as the Minimal Clinically Important Difference for the trial.

    Time frame: at 6 months after end of treatment

Secondary outcomes

  1. Assessment of Quality of Life

    Outcome measure: completion of EORTC QLQ-C30 questionnaire

    Time frame: Baseline; at week 3 & 6 during treatment; at 1,3, 6, 12 and 24 months after end of treatment

  2. Assessment of Quality of Life

    Outcome measure: completion of EORTC QLQ-H\&N43 module questionnaire

    Time frame: Baseline; at week 3 & 6 during treatment; at 1,3, 6, 12 and 24 months after end of treatment

  3. Assessment of Quality of Life

    Outcome measure: completion of FACT-HN questionnaire

    Time frame: Baseline; at week 3 & 6 during treatment; at 1,3, 6, 12 and 24 months after end of treatment

  4. Assessment of chemo-radiotherapy treatment related toxicities and PEG tube placement complications

    Outcome measure: Incidence, type and severity of all adverse events (AEs) and serious adverse events according to CTCAE version 5.0 ;

    Time frame: through study completion, an average of 38 months

  5. Assessment of chemo-radiotherapy treatment related toxicities and PEG tube placement complications

    Outcome measure:Incidence, type and severity of radiotherapy related AEs also according to Radiation Therapy Oncology Group (RTOG) / European Organisation for Research and treatment of Cancer (EORTC) scores; In the RTOG/EORTC Late Radiation Morbidity Scoring, 0 means an absence of radiation effects and 5 means the effects led to death. The severity of reactions is graded from 1 through 4.

    Time frame: through study completion, an average of 38 months

  6. Assessment of chemo-radiotherapy treatment related toxicities and PEG tube placement complications

    Outcome measure:Severity of oropharyngeal mucositis and swallowing disorders according to Internal consensus scale (ICS);

    Time frame: through study completion, an average of 38 months

  7. Assessment of chemo-radiotherapy treatment related toxicities and PEG tube placement complications

    Outcome measure: Oropharyngeal mucositis according to the oral mucositis weekly questionnaire-Head and Neck cancer (OMWQ-NH) completed by the subject;

    Time frame: through study completion, an average of 38 months

  8. Assessment of chemo-radiotherapy treatment related toxicities and PEG tube placement complications

    Outcome measure: Salivary toxicity according to the xerostomia questionnaire completed by the subject.

    Time frame: through study completion, an average of 38 months

  9. Impact of the nutritional status on survival and toxicity outcomes

    Outcome measure: Clinical dietitian assessment including risk screening by Nutritional Risk Screening 2002 (NRS-2002)

    Time frame: Baseline, during treatment period (7 weeks) and follow-up period (24 months)

  10. Impact of the nutritional status on survival and toxicity outcomes

    Outcome measure: Clinical dietitian assessment using GLIM criteria (Global Leadership Initiative on Malnutrition criteria).

    Time frame: Baseline, during treatment period (7 weeks) and follow-up period (24 months)

  11. Assessment of clinical tumour response after study treatment

    Outcome measure:Tumour response after study treatment measured by DECT and PET-CT

    Time frame: at 3 and 12 months after end of treatment

  12. Assessment of the subject outcome

    Outcome measure: loco regional control (LRC)

    Time frame: at 3, 12 and 36 months after end of treatment

  13. Assessment of the subject outcome

    Outcome measure: distant recurrence/distant progression (DR/DP)

    Time frame: at 3, 12 and 36 months after end of treatment

  14. Assessment of the subject outcome

    Outcome measure: second primary (SP)

    Time frame: at 3, 12 and 36 months after end of treatment

  15. Assessment of the subject outcome

    Outcome measure: disease-free survival (DFS)

    Time frame: at 3, 12 and 36 months after end of treatment

  16. Assessment of the subject outcome

    Outcome measure: disease specific survival (DSS)

    Time frame: at 3, 12 and 36 months after end of treatment

  17. Assessment of the subject outcome

    Outcome measure: overall survival (OS)

    Time frame: at 3, 12 and 36 months after end of treatment

  18. Impact of tobacco consumption on the outcomes

    Outcome measure: Assessment of the smoking consumption

    Time frame: Baseline, at week 3 and at 1, 3, 6, 12 and 24 months after the end of treatment.

  19. Impact of HPV on the outcomes

    Outcome measure: HPV/p16 status

    Time frame: at screening

  20. Cost-Effectiveness of each treatment strategy

    Outcome measure: EuroQol 5D5L Questionnaire

    Time frame: during the pre-study treatment period (within 15 days after randomisation and before starting study treatment) and at 12 months after end of treatment

  21. Clinical validation of cancer prediction models available at www.predictcancer.org

    HPV-based prognostic nomogram for oro-pharyngeal carcinoma

    Time frame: at 6 months after treatment

  22. Clinical validation of cancer prediction models available at www.predictcancer.org

    prediction tool for swallowing dysfunction, xerostomia, sticky saliva and tube feeding dependence

    Time frame: at 6 months after treatment

07

Study locations

1 of 2 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2019 (actual). Primary completion is estimated for Nov 2027, 94 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 10, 2019
First posted
Jul 15, 2019
StartActual
Dec 16, 2019
Primary completionEst.
Nov 1, 2027
CompletionEst.
May 1, 2030
Last update
May 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04019548
Responsible party
Sponsor
First posted
Jul 15, 2019
Start date
Dec 16, 2019
Primary completion
Nov 1, 2027 (estimated)
Completion
May 1, 2030 (estimated)
Last update
May 10, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cisplatin

Start the discussion